| Literature DB >> 35782337 |
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease worldwide, ranging from simple steatosis and nonalcoholic steatohepatitis to fibrosis, cirrhosis, and hepatocellular carcinoma. Acupuncture is a long-established treatment in traditional Chinese medicine. In recent years, increasing evidence has pointed to the effectiveness of acupuncture in the treatment of NAFLD, and a certain degree of progress has been made in the study of related mechanisms. However, previous systematic reviews have not discussed the characteristics and the related mechanisms of acupuncture in the treatment of NAFLD. Therefore, this review synthesizes the progress in research on acupuncture in the context of NAFLD treatment by the inhibition of inflammatory responses, regulation of lipid metabolism disorder, treatment of insulin resistance, antagonization of oxidative stress injury, and interference with endoplasmic reticulum stress. Overall, we sought to highlight the latest research results, potential applications, and ongoing challenges of this therapy.Entities:
Year: 2022 PMID: 35782337 PMCID: PMC9242809 DOI: 10.1155/2022/5259088
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 1.919
Figure 1The location and distribution of the acupuncture points.
Mechanisms of acupuncture intervention in nonalcoholic fatty liver disease.
| Category | Research object | Acupuncture points | Mechanism of action | Reference | Year |
|---|---|---|---|---|---|
| Inhibit inflammation | Rat | Pi shu (BL20), Shen shu (BL23), and Ge shu (BL17) | Inhibits TNF- | [ | 2014 Y |
| Rat | Zu san li (ST36), San yin jiao (SP6), and Feng long (ST40) | Inhibits TNF- | [ | 2018 Y | |
| Rat | Zu san li (ST36), San yin jiao (SP6), and Feng long (ST40) | Inhibits IL-6 expression | [ | 2014 Y | |
| Rat | Feng long (ST40), Zu san li (ST36) | Inhibits TNF- | [ | 2018 Y | |
| Rat | Zu san li (ST36), San yin jiao (SP6), Feng long (ST40), and Tai chong (LR3) | Inhibits IL-18 expression | [ | 2013Y | |
| Rat | Yin ling quan (SP9), Feng long (ST40), and San yin jiao (SP6) | Regulates Sirt1/NF- | [ | 2020Y | |
| Improve lipid metabolism disorder | Mice | Zu san li (ST36), Guan yuan (CV4), and Yong quan (KI1) | Reduces lipid synthesis and promotes lipid metabolism | [ | 2019Y |
| Person | Feng long (ST40), Zu san li (ST36) | Improves hemorheological index | [ | 2021Y | |
| Mice | Zu san li (ST36), Guan yuan (CV4), and Yong quan (KI1) | Inhibits intestinal lipid absorption and reduces lipid accumulation | [ | 2020Y | |
| Antagonize oxidative stress | Rat | Double side tape (GB26) | Decreases MDA content and increases t-SOD and GSH-Px activities | [ | 2019Y |
| Mice | Zu san li (ST36), Guan yuan (CV4), and Yong quan (KI1) | Inhibits the expression of 8-OHdG and TBARS and increases the expression of GPX1, 2, 3, and GSS | [ | 2019Y | |
| Mice | Zu san li (ST36), Guan yuan (CV4), and Yi yu (EX-B3) | Decreases MDA content and increases SOD activity, as well as regulates apoptosis expression of Bax and Bcl-2 | [ | 2020Y | |
| Improve endoplasmic reticulum stress | Rat | Feng long (ST40), San yin jiao (SP6) | Inhibits the expression of SrebP-1C and downregulates FAS activity | [ | 2018Y |
| Rat | Feng long (ST40), Zu san li (ST36) | Inhibits the expression of SrebP-1C | [ | 2017Y | |
| Rat | Zu san li (ST36), San yin jiao (SP6) | Inhibits the expression of SrebP-1C | [ | 2016Y | |
| Rat | Zu san li (ST36), San yin jiao (SP6) | Inhibits the expression of GRP78 | [ | 2016Y | |
| Improve insulin resistance | Rat | Zu san li (ST36), San yin jiao (SP6), Feng long (ST40), and Tai chong (LR3) | Decreases the levels of FPG, FINS and HOMA-IR, and FFA concentration | [ | 2008Y |
| Person | Zhong wan (CV12), Qu chi (LI11), Shui fen (CV9), Guan yuan (CV4), Qi hai (CV6), Feng long (ST40), San yin jiao (SP6), Tai chong (LR3), Xue hai (SP10), Hua rou men (ST24), and Da heng (SP15) | Decreases the levels of FPG, FINS, and HOMA-IR | [ | 2020Y | |
| Rat | Feng long (ST40), Tai chong (LR3) | Increases ADP levels and reduces LP, FFA, and CREP levels | [ | 2018Y | |
| Rat | Feng long (ST40), San yin jiao (SP6) | Inhibits the IKK/NF- | [ | 2021Y | |
| Rat | Zu san li (ST36), Feng long (ST40), Zhong wan (CV12), and Guan yuan (CV4) | Activates the SIRT1/ATG7 pathway and reduces liver fat deposition | [ | 2021Y |